Bimini Biotech Secures €3 Million in Investment Round

A Venture Challenge winner BIMINI Biotech, successfully closed a seed investment round of EUR 3 million. The round was led by San Diego-based (US) Torrey Pines Investment (“TPI”), with the participation of InnovationQuarter Capital (“IQC”), Libertatis Ergo Holding (“LEH”) and a business angel. The funding will enable BIMINI Biotech to progress the preclinical development of its first-in-class modulators of the Wiskott Aldrich Syndrome Protein (WASp).

BIMINI Biotech is a preclinical stage company developing novel first-in-class small molecule therapeutics in oncology with a focus on lymphomas and leukemia, malignancies with a strong unmet need. The company was established in 2019 and is based in Leiden (The Netherlands).

 “We are excited to welcome this group of experienced investors and to have the continued support of our existing shareholders. This funding allows us to take significant steps in advancing the development of our groundbreaking WASp modulators.” - CEO Dr. Digvijay Gahtory 

This investment brings Bimini Biotech closer to its mission of improving treatment options for patients with aggressive forms of leukemia and lymphoma.

For more information about Bimini Biotech and their innovative approach, visit biminibiotech.nl.